High BCR-ABLIS expression at diagnosis and after 3 and 6 months of treatment are associated with unfavourable responses to Imatinib

Vitale S. R.;Stagno F.;Stella S.;Cupri A.;Forte S.;Massimino M.;Antolino A.;Abbadessa V.;Brugiatelli M.;Guglielmo P.;Musolino C.;Turri D.;Russo M.;Pagnucco G.;Rizzo M.;Musso M.;Morabito F.;Levato L.;MANZELLA, LIVIA;Muller M. C.;DI RAIMONDO, FRANCESCO;VIGNERI, PAOLO

2012-01-01